Rexahn Pharmaceuticals, Inc. (NYSE:RNN)‘s stock had its “outperform” rating reiterated by research analysts at FBR & Co in a report released on Thursday. They currently have a $3.00 price objective on the stock.

Separately, Zacks Investment Research upgraded shares of Rexahn Pharmaceuticals from a “hold” rating to a “buy” rating and set a $0.25 price objective for the company in a report on Friday, August 12th.

Shares of Rexahn Pharmaceuticals (NYSE:RNN) traded down 9.1500% during trading on Thursday, hitting $0.1817. The stock had a trading volume of 2,780,388 shares. The firm’s market cap is $38.76 million. The firm’s 50-day moving average is $0.23 and its 200-day moving average is $0.27. Rexahn Pharmaceuticals has a one year low of $0.18 and a one year high of $0.52.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at

Rexahn Pharmaceuticals (NYSE:RNN) last issued its quarterly earnings data on Monday, August 8th. The company reported ($0.01) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.02) by $0.01. Equities research analysts forecast that Rexahn Pharmaceuticals will post ($0.07) EPS for the current year.

A hedge fund recently raised its stake in Rexahn Pharmaceuticals stock. Vanguard Group Inc. boosted its position in shares of Rexahn Pharmaceuticals, Inc. (NYSE:RNN) by 1.0% during the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 4,904,097 shares of the company’s stock after buying an additional 49,761 shares during the period. Vanguard Group Inc. owned approximately 2.30% of Rexahn Pharmaceuticals worth $1,232,000 at the end of the most recent reporting period.

About Rexahn Pharmaceuticals

Rexahn Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company engaged in the discovery, development and commercialization of treatments for cancer. The Company’s clinical-stage drug candidates in active development include Archexin, RX-3117 and Supinoxin (RX-5902). Archexin is a potent inhibitor of the protein kinase Akt-1, which focuses on cancer cell proliferation, survival, angiogenesis, metastasis and drug resistance.

5 Day Chart for NYSE:RNN

Receive News & Ratings for Rexahn Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rexahn Pharmaceuticals Inc. and related companies with's FREE daily email newsletter.